More than 52 million doses of BEXSERO have been distributed worldwide since 2015.1
BEXSERO is approved in 40+ countries, including Canada, Australia, and much of Europe.2
BEXSERO was used in response to outbreaks on major college campuses, including3:
- Princeton University4
- University of Wisconsin–Madison5
See a real college student’s MenB survival story
> WATCH RAYNA’S STORY
MenB=meningococcal serogroup B.
BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals aged 10 through 25 years.
Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.